PharmChem Inc
OTC:PCHM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (11.2), the stock would be worth $3.52 (6% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 12 | $3.75 |
0%
|
| 3-Year Average | 11.2 | $3.52 |
-6%
|
| 5-Year Average | 7 | $2.19 |
-42%
|
| Industry Average | 18.7 | $5.86 |
+56%
|
| Country Average | 16.7 | $5.23 |
+40%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
P
|
PharmChem Inc
OTC:PCHM
|
17.2m USD | 12 | 12.5 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
97.1B USD | 13.8 | 54.9 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.3B EUR | 10.6 | 13.3 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.4B USD | 0 | 12.1 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.9B EUR | 12.7 | 18.9 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23B EUR | 11 | 23.5 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.4B USD | 14.4 | 22.7 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.4B USD | 16.4 | 25.5 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.9B EUR | 6.5 | 11.2 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.7B USD | -66.1 | -28.1 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 10.4 | 14 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
PharmChem Inc
Glance View
PharmChem, Inc. engages in the provision of integrated drug testing services. The company is headquartered in Fort Worth, Texas and currently employs 170 full-time employees. The firm PharmChek Sweat Patch (or Drug Patch) is worn on the skin for up to 10 days and uses sweat as the specimen source. PharmChek kits include PharmChek 50ct. Kit + Standard Panel (N228), PharmChek 50ct. Kit + Standard + Expanded Panel (N229), PharmChek 10ct. Kit + Standard Panel (N225) and PharmChek 10ct. Kit + Standard + Expanded Panel (N226). Its products also include PharmChek Overlay, and PharmChek Analysis Panels, which consist of cocaine, opiates, methamphetamine, amphetamine, marijuana and phencyclidine. Its training modules include construction, storage, wear time, application, removal, shipping and lab screening/confirmation.
